NFL Hall of Fame Legend Fred Biletnikoff Joins AFL/Signalife Cardiovascular Protection Team
The MVP of Super Bowl XI, Mr. Biletnikoff demonstrated on a world stagewhat passion and focus mean as he delivered an unprecedented performance inleading his team to an overwhelming victory in the Super Bowl.
In 1999, Mr. Biletnikoff was ranked number 94 on The Sporting News "listof the 100 Greatest Football Players." The Fred Biletnikoff Award, awardedannually to the best wide receiver in college football since 1994, was namedin his honor.
Dr. Harmison, former Principal Deputy of the U.S. Department of HealthServices, commented: "Mr. Biletnikoff -- one of my personal heroes -- hasmade the choice to make a difference in a disease-state that burdenspractically every family in America and costs the U.S. Health Care industryabout $400 billion per year in treating cardiovascular disease. Havingsomeone of his stature -- a true NFL legend -- and of his demographic, willassist Signalife and AFL in addressing all of the different possible diseasestates and treatment options in a wider array of circumstances. I very muchappreciate Mr. Biletnikoff's decision to join our cause to level the playingfield for everyone."
Signalife, Inc. is a life sciences company focused on the monitoring anddetection of disease through continuous biomedical signal monitoring.Signalife uses its patented signal technology to design and develop medicaldevices that simplify and reduce the costs of diagnostic testing and patientmonitoring in an ambulatory setting.
Signalife is publicly traded on the American Stock Exchange under thesymbol SGN. The website for the company is http://www.Signalife.com. ClearData. Trusted Results.
Caution Regarding Forward-Looking Statements
Statements in this release that are not strictly historical are "forward-looking" statements. Forward-looking statements involve known and unknownrisks, which may cause Signalife's actual results in the future to differmaterially from expected results. Factors which could cause or contribute tosuch differences include, but are not limited to, failure to complete thedevelopment and introduction of heart monitoring and other biomedical devicesincorporating Signalife's technology, failure to obtain federal or stateregulatory approvals governing heart monitoring and other biomedical devicesincorporating Signalife's technology, inability to obtain physician, patientor insurance acceptance of for heart monitoring and other biomedicalincorporating Signalife's technology, and the unavailability of financing tocomplete management's plans and objectives, including the development of heartmonitoring and other biomedical incorporating Signalife's technology. Theserisks are qualified in their entirety by cautionary language and risk factorsset forth and to be further described in Signalife's filings with theSecurities and Exchange Commission.
SOURCE Signalife, Inc.
You May Also Like